Scrip
>>Business
>>Start-Ups & SMEs

Iterum Therapeutics Focused On First Oral Penem

13 Jul 2017

• By John Davis

Emerging Company Profile: Iterum Therapeutics is developing a Phase III-ready penem antibiotic, sulopenem, which could be the first in its class to be administered orally. It’s the second foray into setting up an anti-infectives-focused company by a team of experienced biotech executives and entrepreneurs that previously took Durata’s dalbavancin through clinical development.

Urinary Tract Infections (UTIs) are to be targeted by sulopenem • Source: Shutterstock

Dublin, Ireland and Chicago, Illinois-based Iterum Therapeutics Ltd., set up in 2015 by a small team of biotech executives and a VC syndicate, has in its sights the development of the first penem antibiotic that can be administered orally, sulopenem.

The compound can also be administered intravenously and has a broad spectrum of activity, making it potentially useful for both...